ArticleNPJ digital medicine2025
A group concept mapping study of stakeholder perspectives on digital therapeutics economic value drivers.
Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Understanding Economic Decision-Making in Digital Therapeutics Development: Qualitative Approach.Journal of medical Internet research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digital therapeutics (DTx), software as a medical device, present a promising avenue for addressing the increasing burden of a range of conditions, yet their widespread implementation remains contingent upon demonstrating economic value-an understudied domain in current literature. Using a Group Concept Mapping approach, this study synthesized perspectives from healthcare professionals, researchers, industry, and public sector representatives to understand factors perceived to influence DTx economic value throughout its lifecycle. Analysis revealed 59 factors organized into eight clusters. Stakeholders consistently identified DTx Impact on Patient Outcomes and DTx Implementation as the most influential clusters affecting economic value. However, DTx Associated Costs and DTx Monetization Models clusters were reported as not receiving sufficient consideration throughout the DTx development lifecycle, particularly among researchers. Consequently, a conceptual framework of priority clusters and factors driving DTx economic value is proposed.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.